Contact
searchSearch
HMP Global
Login

Abstracts Topic Center

Abstracts
Enhancing Oncology Documentation and Diagnosis Capture With Integrated AI Scribe in Electronic Health Record
08/25/2025
Eileen Campetti, PA-C, MS; Saranga Arora, MS, MBA; Helena Hay; Jennifer Siggia, RN, MSN; Stephen Speicher, MD, MS
In a pre-post study across 258 oncology clinics, integration of DeepScribe’s oncology-specific artificial intelligence (AI) scribe into the Flatiron Health OncoEMR electronic health record (EHR) system resulted in high adoption (98%),...
In a pre-post study across 258 oncology clinics, integration of DeepScribe’s oncology-specific artificial intelligence (AI) scribe into the Flatiron Health OncoEMR electronic health record (EHR) system resulted in high adoption (98%),...
In a pre-post study across 258...
08/25/2025
Journal of Clinical Pathways
Abstracts
Provision of Comparative Clinical Evidence to Support Pathway Decision-Making
08/25/2025
Aimee Ginsburg, PharmD, BCPS; Daniel Rubin, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP
Initially developed to support the Pathways Task Force (PTF) within the Value Pathways powered by the National Comprehensive Cancer Network (NCCN), embedded evidence tables summarizing clinical trial data—including patient-reported...
Initially developed to support the Pathways Task Force (PTF) within the Value Pathways powered by the National Comprehensive Cancer Network (NCCN), embedded evidence tables summarizing clinical trial data—including patient-reported...
Initially developed to support...
08/25/2025
Journal of Clinical Pathways
Abstracts
Assessing EHR-to-EDC Data Transfer Solutions
08/25/2025
Kristy L. Johnson; Jeffrey Minehart; Molly Lieber
In a pilot study at UChicago Medicine, Flatiron Clinical Pipe—a study-agnostic electronic health record (EHR)–to–electronic data capture (EDC) integration tool—automated the transfer of 4700 structured data points across two gastrointestinal...
In a pilot study at UChicago Medicine, Flatiron Clinical Pipe—a study-agnostic electronic health record (EHR)–to–electronic data capture (EDC) integration tool—automated the transfer of 4700 structured data points across two gastrointestinal...
In a pilot study at UChicago...
08/25/2025
Journal of Clinical Pathways
Abstracts
Green Light, Red Flags: A New Framework for Evaluating Oncology Accelerated Approvals
08/25/2025
Sang Chau, PharmD, BCOP; Justin R. Tse, PharmD, BCOP; Amy VanGalder, PharmD, BCOP; Terra Wonsettler, PharmD, MBA; Andrew Hertler, MD, FACP
To improve transparency and consistency in evaluating oncology therapies granted US Food and Drug Administration (FDA) Accelerated Approval (AA), Evolent developed the Clinical Benefit Index (CBI)—a framework combining the European Society...
To improve transparency and consistency in evaluating oncology therapies granted US Food and Drug Administration (FDA) Accelerated Approval (AA), Evolent developed the Clinical Benefit Index (CBI)—a framework combining the European Society...
To improve transparency and...
08/25/2025
Journal of Clinical Pathways
Abstracts
Streamlining Clinical Decision Support Through Integrated Education
08/25/2025
Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
To improve workflow efficiency and clinical decision-making, the Clear Value Plus (CVP) clinical decision support (CDS) tool integrated Launch N’ Learn—an embedded feature providing point-of-care access to staging criteria and guideline-based...
To improve workflow efficiency and clinical decision-making, the Clear Value Plus (CVP) clinical decision support (CDS) tool integrated Launch N’ Learn—an embedded feature providing point-of-care access to staging criteria and guideline-based...
To improve workflow efficiency...
08/25/2025
Journal of Clinical Pathways
Abstracts
From Approval to Action: Evaluating Review Timelines for Oncology Therapies in Value Pathways
08/25/2025
Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
A retrospective analysis of 84 oncology drug approvals from January 2024 to June 2025 demonstrated that the US Oncology Network’s Pathways Task Force (PTF) conducted timely reviews—averaging 54 days post–US Food and Drug Administration (FDA)...
A retrospective analysis of 84 oncology drug approvals from January 2024 to June 2025 demonstrated that the US Oncology Network’s Pathways Task Force (PTF) conducted timely reviews—averaging 54 days post–US Food and Drug Administration (FDA)...
A retrospective analysis of 84...
08/25/2025
Journal of Clinical Pathways
Abstracts
Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer
08/25/2025
Daniel Rubin, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within...
08/25/2025
Journal of Clinical Pathways
Abstracts
Modification of PARP Inhibitor Use in mCRPC With Co-Occurring BRCA1/2 Mutations and MSI-High Status
08/25/2025
Steven Gilmore, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS; Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Dhaval Shah, MBBS
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US...
08/25/2025
Journal of Clinical Pathways
Abstracts
Efficacy, Safety, and End-of-Treatment Mutational Results From the 5-Year Follow-Up of the Phase 2 OPTIC Study in Patients With Chronic-Phase Chronic Myeloid Leukemia
08/25/2025
Jorge Cortes, MD; Michael Deininger, MD, PhD; Jane Apperley, MD; Andreas Hochhaus, MD; Hugues de Lavallade, MD, PhD; Jeffrey Lipton, MD, PhD; Elza Lomaia, MD, PhD; James McCloskey, MD; Lori Maness, MD; Michael Mauro, MD; Beatriz Moiraghi, MD; Carolina Pavlovsky, MD; Gianantonio Rosti, MD; Philippe Rousselot, MD, PhD; Maria Undurraga Sutton, MD; Bo Chao, MS; Alexander Vorog, MD; Tammie Yeh, PhD; Niti Patel, PhD; Hagop Kantarjian, MD
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC...
08/25/2025
Journal of Clinical Pathways
Abstracts
Ensuring Access to Care: Using Tax-Exempt and Taxable Bond Funding for Consolidation of Outpatient Specialties
08/25/2025
Greg Merrill
Faced with rising operational costs and declining reimbursement, Radiation Business Solutions created a tax-exempt, bond-funded not-for-profit model to consolidate four independent for-profit cancer centers in Alaska, demonstrating that...
Faced with rising operational costs and declining reimbursement, Radiation Business Solutions created a tax-exempt, bond-funded not-for-profit model to consolidate four independent for-profit cancer centers in Alaska, demonstrating that...
Faced with rising operational...
08/25/2025
Journal of Clinical Pathways
Abstracts
Streamlining Clinical Decision Support Through Integrated Education
08/25/2025
Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
To improve workflow efficiency and clinical decision-making, the Clear Value Plus (CVP) clinical decision support (CDS) tool integrated Launch N’ Learn—an embedded feature providing point-of-care access to staging criteria and guideline-based...
To improve workflow efficiency and clinical decision-making, the Clear Value Plus (CVP) clinical decision support (CDS) tool integrated Launch N’ Learn—an embedded feature providing point-of-care access to staging criteria and guideline-based...
To improve workflow efficiency...
08/25/2025
Journal of Clinical Pathways
Abstracts
From Approval to Action: Evaluating Review Timelines for Oncology Therapies in Value Pathways
08/25/2025
Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
A retrospective analysis of 84 oncology drug approvals from January 2024 to June 2025 demonstrated that the US Oncology Network’s Pathways Task Force (PTF) conducted timely reviews—averaging 54 days post–US Food and Drug Administration (FDA)...
A retrospective analysis of 84 oncology drug approvals from January 2024 to June 2025 demonstrated that the US Oncology Network’s Pathways Task Force (PTF) conducted timely reviews—averaging 54 days post–US Food and Drug Administration (FDA)...
A retrospective analysis of 84...
08/25/2025
Journal of Clinical Pathways
Abstracts
Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer
08/25/2025
Daniel Rubin, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within...
08/25/2025
Journal of Clinical Pathways
Abstracts
Modification of PARP Inhibitor Use in mCRPC With Co-Occurring BRCA1/2 Mutations and MSI-High Status
08/25/2025
Steven Gilmore, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS; Victoria Handy, PharmD, BCOP; Daniel Rubin, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Dhaval Shah, MBBS
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor...
Following an update to the US...
08/25/2025
Journal of Clinical Pathways
Abstracts
Efficacy, Safety, and End-of-Treatment Mutational Results From the 5-Year Follow-Up of the Phase 2 OPTIC Study in Patients With Chronic-Phase Chronic Myeloid Leukemia
08/25/2025
Jorge Cortes, MD; Michael Deininger, MD, PhD; Jane Apperley, MD; Andreas Hochhaus, MD; Hugues de Lavallade, MD, PhD; Jeffrey Lipton, MD, PhD; Elza Lomaia, MD, PhD; James McCloskey, MD; Lori Maness, MD; Michael Mauro, MD; Beatriz Moiraghi, MD; Carolina Pavlovsky, MD; Gianantonio Rosti, MD; Philippe Rousselot, MD, PhD; Maria Undurraga Sutton, MD; Bo Chao, MS; Alexander Vorog, MD; Tammie Yeh, PhD; Niti Patel, PhD; Hagop Kantarjian, MD
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib—starting at 45 mg daily and reducing to 15 mg upon achieving major molecular response—provides sustained efficacy and manageable safety in...
The 5-year results of the OPTIC...
08/25/2025
Journal of Clinical Pathways
Abstracts
Ensuring Access to Care: Using Tax-Exempt and Taxable Bond Funding for Consolidation of Outpatient Specialties
08/25/2025
Greg Merrill
Faced with rising operational costs and declining reimbursement, Radiation Business Solutions created a tax-exempt, bond-funded not-for-profit model to consolidate four independent for-profit cancer centers in Alaska, demonstrating that...
Faced with rising operational costs and declining reimbursement, Radiation Business Solutions created a tax-exempt, bond-funded not-for-profit model to consolidate four independent for-profit cancer centers in Alaska, demonstrating that...
Faced with rising operational...
08/25/2025
Journal of Clinical Pathways
Abstracts
From Fragmented to Integrated: A Roadmap to Equity for Psychosocial Support in Rural and Underserved Cancer Programs
08/25/2025
Jerlinda Ross, MD, MS, MBA; James Emery, PhD
An environmental scan revealed that integrating psychosocial care into oncology programs—especially in underserved and rural communities—is hindered by systemic and structural barriers, prompting the development of a strategic four-part...
An environmental scan revealed that integrating psychosocial care into oncology programs—especially in underserved and rural communities—is hindered by systemic and structural barriers, prompting the development of a strategic four-part...
An environmental scan revealed...
08/25/2025
Journal of Clinical Pathways
Abstracts
Pharmacist-Driven Outcomes for Patients on Oral Oncology Medications: Clinical Impact of an Integrated Specialty Pharmacy Model
08/25/2025
Kishen Patel, PharmD; Martha Stutsky, PharmD; Y. Caleb Chun, MA; Shreevidya Periyasamy, MS; Chelsey Lindner, PharmD, BCOP
In a retrospective evaluation of 6668 patients receiving oral oncology medications through an academic health system specialty pharmacy (HSSP), pharmacist-led interventions—primarily targeting drug safety and adherence—were associated with...
In a retrospective evaluation of 6668 patients receiving oral oncology medications through an academic health system specialty pharmacy (HSSP), pharmacist-led interventions—primarily targeting drug safety and adherence—were associated with...
In a retrospective evaluation of...
08/25/2025
Journal of Clinical Pathways
Abstracts
Cost-Effectiveness of BTKis in Medicare Patients With CLL in First-Line and Relapsed/Refractory Settings
08/25/2025
Bhavini Srivastava, MSc; Huimin Li, MA; Pam Martin, PhD; James Gahn, BS; Shaffee Bacchus, PharmD; Erin Franceschini, MS; Kavita Sail, PhD
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a...
08/25/2025
Journal of Clinical Pathways
Abstracts
Enhancing Oncology Documentation and Diagnosis Capture With Integrated AI Scribe in Electronic Health Record
08/25/2025
Eileen Campetti, PA-C, MS; Saranga Arora, MS, MBA; Helena Hay; Jennifer Siggia, RN, MSN; Stephen Speicher, MD, MS
In a pre-post study across 258 oncology clinics, integration of DeepScribe’s oncology-specific artificial intelligence (AI) scribe into the Flatiron Health OncoEMR electronic health record (EHR) system resulted in high adoption (98%),...
In a pre-post study across 258 oncology clinics, integration of DeepScribe’s oncology-specific artificial intelligence (AI) scribe into the Flatiron Health OncoEMR electronic health record (EHR) system resulted in high adoption (98%),...
In a pre-post study across 258...
08/25/2025
Journal of Clinical Pathways

BDHC thumbnail
Videos
Recognizing the Importance of Primary Care in Cancer Care Delivery
08/04/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the undervalued yet critical role of primary care in the health care ecosystem—especially in oncology—highlighting its impact on early detection,...
In this episode of Breaking Down...
08/04/2025
Cancer Care Business Exchange
BDHC Thumbnail
Videos
What Medical School Doesn’t Teach: Real-World Readiness in US Health Care
06/11/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this edition of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the limitations of current medical education—from outdated testing and board certification to gaps in real-world practice preparedness—and call for...
In this edition of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the limitations of current medical education—from outdated testing and board certification to gaps in real-world practice preparedness—and call for...
In this edition of Breaking Down...
06/11/2025
Cancer Care Business Exchange
BDHC Thumbnail
Videos
Evolving Remote Engagement in Oncology: Beyond the Telehealth Visit
05/05/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej discuss the evolution of remote patient engagement in oncology—from the rapid expansion of telemedicine during COVID-19 to the growing role of tools like...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej discuss the evolution of remote patient engagement in oncology—from the rapid expansion of telemedicine during COVID-19 to the growing role of tools like...
In this episode of Breaking Down...
05/05/2025
Cancer Care Business Exchange
BDHC Thumbnail
Videos
When Capital Meets Care: Examining the Role of Private Equity in Oncology
04/07/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy, MBA, and Dr Michael Kolodziej, MD, explore the complex and evolving role of private equity in health care, weighing its potential to drive innovation and efficiency against concerns...
In this episode of Breaking Down Health Care, John Hennessy, MBA, and Dr Michael Kolodziej, MD, explore the complex and evolving role of private equity in health care, weighing its potential to drive innovation and efficiency against concerns...
In this episode of Breaking Down...
04/07/2025
Cancer Care Business Exchange
BDHC Thumbnail
Videos
Expanding Access to Clinical Trials: What Oncologists and Payers Need to Know
02/28/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy, MBA, and Michael Kolodziej, MD, explore the evolving landscape of oncology clinical trials, discussing the challenges of patient enrollment, the impact of pharmaceutical-sponsored...
In this episode of Breaking Down Health Care, John Hennessy, MBA, and Michael Kolodziej, MD, explore the evolving landscape of oncology clinical trials, discussing the challenges of patient enrollment, the impact of pharmaceutical-sponsored...
In this episode of Breaking Down...
02/28/2025
Cancer Care Business Exchange

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use